Friday, July 27, 2012

Drug Discovery@nature.com 27 July 2012

Drug Discovery
TABLE OF CONTENTS

27 July 2012

News
Analysis
Research Highlights
Research & Reviews
Careers


Nature Reviews Drug Discovery is on Twitter

Advertisement
Nature Medicine and the Volkswagen Foundation present:
Herrenhausen Symposium on Metastasis
October 8-10, 2012 - Seeon, Germany

A subset of leaders in the field will attend the Herrenhausen Symposium and participate in an interdisciplinary discussion that will point in the direction of solutions to the greatest challenges that the field of viral pathogenesis faces.

Apply today!
 

News

Top

Europe nears first approval for gene therapy treatment
doi:10.1038/nature.2012.11048
Therapy for rare fat-processing disease gains medicines regulator’s approval.
Full Text

The great gene-patent debate
doi:10.1038/nature.2012.11044
How the Myriad Genetics gene-patent case might affect personalized medicine.
Full Text

Artificial jellyfish built from rat cells
doi:10.1038/nature.2012.11046
Reverse-engineered life form could be used to test drugs.
Full Text

Debate over details of US biosimilar pathway continues to rage
doi:10.1038/nbt0712-577
Despite the publication of draft guidance for biosimilar products early this year, opinions about regulatory standards remain sharply divided.
Full Text

Analysis

Top

PI3Kδ turns schizophrenic
doi:10.1038/scibx.2012.718
NIH researchers have linked phosphoinositide 3-kinase-δ to neuregulin signaling and shown that inhibiting the kinase improved behavior in rodent models of schizophrenia.
Full Text

FDA advisory committee meeting outcomes
doi:10.1038/nrd3747
This analysis of the outcomes of advisory committee meetings held by the US FDA over the past decade investigates issues such as the consistency between advisory committee votes and FDA approval decisions.
Full Text

Pipeline pioneers: Vismodegib
doi:10.1038/nrd3753
First-in-class inhibitor of the Hedgehog signalling pathway approved in the United States for the treatment of basal cell carcinoma.
Full Text

Research Highlights

Top

Cancer: Of targets and anti-targets
doi:10.1038/nrd3781
Polypharmacology is difficult to predict. Now, researchers have taken a systems pharmacology approach, identifying targets and anti-targets for the rational design of drugs with an optimized polypharmacological profile.
Full Text

Metabolic disorders: Heart microRNA provides new route to metabolic control
doi:10.1038/nrd3779
Researchers have discovered a novel role of the heart in systemic metabolic control and suggest that miR-208a inhibition may have applications in the treatment of metabolic disorders.
Full Text

Anticancer drugs: Antipsychotic to anticancer agent?
doi:10.1038/nrd3783
A new study has screened for compounds that selectively differentiate cancer stem cell-like cells and has identified dopamine receptor antagonists as promising candidates.
Full Text

Research & Reviews

Top

Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars
doi:10.1038/nrd3746
This review looks at the analytical technologies available to assess biosimilars, focusing on the assessment of post-translational modifications, three-dimensional structures and protein aggregation.
Full Text

Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
doi:10.1038/nrd3745
This Review discusses the current state of ocular drug therapy and highlights future therapeutic opportunities.
Full Text

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4CD8entheseal resident T cells
doi:10.1038/nm.2817
The identification of an IL-23–responsive CD4CD8 T cell population points to new therapeutic targets for this group of rheumatic disorders.
Full Text

A new isoform of steroid receptor coactivator-1 is crucial for pathogenic progression of endometriosis
doi:10.1038/nm.2826
Researchers have discovered a new axis that mediates the pathogenic progression of endometriosis, and suggest that the antibody to TNF-α etanercept might offer a therapy.
Full Text

Drug Discovery
JOBS of the week
Principal Investigator positions in Biological Chemistry & Drug Discovery
University of Dundee, College of Life Sciences
PhD position - Smart nanoparticles for targeted drug delivery in pulmonary fibrosis
Comprehensive Pneumology Center
Institute Research Scientist – Drug Metabolism
MD Anderson Cancer Center
Sr Research Associate / Principle Investigator – EnVivo Drug Discovery
H3 Biomedicine
PhD studentship on large-scale quantum chemistry methods applied to drug discovery
University of Southampton - Chemistry
More Science jobs from
Drug Discovery
EVENT
Effective Risk Based Applications of cGMPs to Cosmetics and OTC Drug Products
01.-02.10.12
PA, US
More science events from

Careers

Top

Career snapshots archive
Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field.
Full Text

Top
Advertisement
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.

Recommend SciBX to your library today.
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

© Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

No comments: